Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9841488rdf:typepubmed:Citationlld:pubmed
pubmed-article:9841488lifeskim:mentionsumls-concept:C0175677lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0600534lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0022663lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C1412113lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C1958507lld:lifeskim
pubmed-article:9841488lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:9841488pubmed:issue6 Pt 2lld:pubmed
pubmed-article:9841488pubmed:dateCreated1998-11-5lld:pubmed
pubmed-article:9841488pubmed:abstractTextTo elucidate the contribution of the renin-angiontensin system (RAS) to glomerular injury in salt-sensitive hypertension, we investigated the chronic effects of the angiotensin I-converting enzyme inhibitor cilazapril and the angiotensin II type 1-receptor antagonist (AT1a) TCV-116 in Dahl-Iwai rats. Dahl salt-sensitive (S) rats receiving 8% salt diet for 6 wk were simultaneously treated with cilazapril (n = 6), TCV-116 (n = 6), or saline (n = 14). The 8% salt diet markedly increased systolic blood pressure (SBP), urinary protein, and N-acetyl-beta-glucosaminidase (NAG) excretion compared with 0.3% salt-treated S (n = 6) or salt-resistant (n = 6) rats. Although neither cilazapril nor TCV-116 reduced the elevated SBP, TCV-116 significantly lowered urinary protein and NAG excretion. Histologically, 8% salt treatment in S rats induced progressive sclerotic and proliferative glomerular changes, which were ameliorated by both drugs. TCV-116 increased the glomerular diameter. Immunofluorescence demonstrated the increased level of type III collagen in the mesangium of 8% salt-treated S rats, which was completely reversed by TCV-116. Competitive RT-PCR of mRNA extracted from the glomeruli revealed that 8% salt treatment significantly increased the levels of proliferating cell nuclear antigen (PCNA) and platelet-derived growth factor B-chain and that TCV-116 significantly reduced the levels of PCNA and transforming growth factor-beta1 (TGF-beta1). Thus, although the chronic RAS-inhibition in salt-sensitive hypertension exerted a histologically renoprotective effect by both ways without lowering blood pressure, the RAS inhibition due to AT1a had more beneficial advantages of reducing proteinuria and attenuating the levels of glomerular TGF-beta1 and extracellular matrix.lld:pubmed
pubmed-article:9841488pubmed:languageenglld:pubmed
pubmed-article:9841488pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:citationSubsetIMlld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9841488pubmed:statusMEDLINElld:pubmed
pubmed-article:9841488pubmed:monthJunlld:pubmed
pubmed-article:9841488pubmed:issn0002-9513lld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:YamauchiTTlld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:MakinoHHlld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:MimuraYYlld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:OguraTTlld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:OtsukaFFlld:pubmed
pubmed-article:9841488pubmed:authorpubmed-author:KataokaHHlld:pubmed
pubmed-article:9841488pubmed:issnTypePrintlld:pubmed
pubmed-article:9841488pubmed:volume274lld:pubmed
pubmed-article:9841488pubmed:ownerNLMlld:pubmed
pubmed-article:9841488pubmed:authorsCompleteYlld:pubmed
pubmed-article:9841488pubmed:paginationR1797-806lld:pubmed
pubmed-article:9841488pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:meshHeadingpubmed-meshheading:9841488-...lld:pubmed
pubmed-article:9841488pubmed:year1998lld:pubmed
pubmed-article:9841488pubmed:articleTitleEffects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats.lld:pubmed
pubmed-article:9841488pubmed:affiliationDepartment of Medicine III, Okayama University Medical School, Okayama University, Okayama 700-8558 Japan.lld:pubmed
pubmed-article:9841488pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9841488lld:pubmed